Dana-Farber Cancer Institute /ID# 126496

Boston, Massachusetts 02215

0 studies enrolling now · 1 studies all time

What they study most

Chronic Lymphocytic Leukemia

Studies at this site

• A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy — Completed